Cost-effectiveness of a low-calorie diet and orlistat for obese persons: modeling long-term health gains through prevention of obesity-related chronic diseases.

OBJECTIVE Our study estimated the cost-effectiveness of pharmacologic treatment of obesity in combination with a low-calorie diet in The Netherlands. METHODS Costs and effects of a low-calorie diet-only intervention and of a low-calorie diet in combination with 1 year of orlistat were compared to no treatment. The RIVM Chronic Disease Model was used to project the differences in quality adjusted life years (QALYs) and lifetime health-care costs because of the effects of the interventions on body mass index (BMI) status. This was done by linking BMI status to the occurrence of obesity-related diseases and by relating quality of life to disease status. Probabilistic sensitivity analysis was employed to study the effect of uncertainty in the model parameters. In univariate sensitivity analysis, we assessed how sensitive the results were to several key assumptions. RESULTS Incremental costs per QALY gained were Euro 17,900 for the low-calorie diet-only intervention compared to no intervention and Euro 58,800 for the low-calorie diet + orlistat compared to the low-calorie diet only. Assuming a direct relation between BMI and quality of life, these ratios decreased to Euro 6000 per QALY gained and Euro 24,100 per QALY gained. Costs per QALY gained were also sensitive to assumptions about long-term weight loss maintenance. CONCLUSIONS Cost-effectiveness ratios of interventions aiming at weight reduction depend strongly on assumptions regarding the relation between BMI and quality of life. We recommend that a low-calorie diet should be the first option for policymakers in combating obesity.

[1]  P. van Baal,et al.  Increasing tobacco taxes: a cheap tool to increase public health. , 2007, Health policy.

[2]  P. van Baal,et al.  Unrelated medical care in life years gained and the cost utility of primary prevention: in search of a 'perfect' cost-utility ratio. , 2007, Health economics.

[3]  H. Gravelle,et al.  Discounting in economic evaluations: stepping forward towards optimal decision rules. , 2007, Health economics.

[4]  R. Hoogenveen,et al.  Lifestyle Interventions Are Cost-Effective in People With Different Levels of Diabetes Risk , 2007, Diabetes Care.

[5]  T. Groves,et al.  Opinion leader interventions in social networks , 2006, BMJ : British Medical Journal.

[6]  P. van Baal,et al.  Estimating health-adjusted life expectancy conditional on risk factors: results for smoking and obesity , 2006, Population health metrics.

[7]  W. Brouwer,et al.  A dollar is a dollar is a dollar--or is it? , 2006, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[8]  T. Harris,et al.  Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. , 2006, The New England journal of medicine.

[9]  K. Kuntz,et al.  Economic Evaluation of Weight Loss Interventions in Overweight and Obese Women , 2006, Obesity.

[10]  P. van Baal,et al.  Disability weights for comorbidity and their influence on Health-adjusted Life Expectancy , 2006, Population health metrics.

[11]  F. G. Schellevis,et al.  Morbidity, Performance and Quality in Primary Care: A Practical Guide, v. 2 , 2006 .

[12]  D. Foxcroft,et al.  Orlistat for the treatment of obesity: cost utility model , 2005, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[13]  M. Postma,et al.  Need for differential discounting of costs and health effects in cost effectiveness analyses , 2005, BMJ : British Medical Journal.

[14]  A. Wolf,et al.  Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland , 2005, International Journal of Obesity.

[15]  R. Hoogenveen,et al.  Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[16]  P. Shekelle,et al.  Meta-Analysis: Pharmacologic Treatment of Obesity , 2005, Annals of Internal Medicine.

[17]  David B Allison,et al.  Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. , 2004, Circulation.

[18]  P. Zelissen,et al.  [Treatment of overweight and obesity in adults: proposal for a guideline]. , 2004, Nederlands tijdschrift voor geneeskunde.

[19]  W. Brouwer,et al.  Decision makers' views on health care objectives and budget constraints: results from a pilot study. , 2004, Health policy.

[20]  Alan D. Lopez,et al.  the Global Burden of Disease , 2004 .

[21]  A. Brennan,et al.  Cost-Effectiveness of Sibutramine in the Treatment of Obesity , 2004, Medical decision making : an international journal of the Society for Medical Decision Making.

[22]  R. Hoogenveen,et al.  Future burden and costs of smoking-related disease in the Netherlands: a dynamic modeling approach. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[23]  K. Mcinnis.  Diet, Exercise, and the Challenge of Combating Obesity in Primary Care , 2003, The Journal of cardiovascular nursing.

[24]  E. Tong,et al.  Transitioning adolescents with congenital heart disease into adult health care. , 2003, Progress in cardiovascular nursing.

[25]  M. Sculpher,et al.  Representing uncertainty: the role of cost-effectiveness acceptability curves. , 2001, Health economics.

[26]  W. Saris.  Very-low-calorie diets and sustained weight loss. , 2001, Obesity research.

[27]  James W. Anderson,et al.  Long-term weight-loss maintenance: a meta-analysis of US studies. , 2001, The American journal of clinical nutrition.

[28]  N. Finer.  Low-calorie diets and sustained weight loss. , 2001, Obesity research.

[29]  M. Essink‐bot,et al.  A national burden of disease calculation: Dutch disability-adjusted life-years. Dutch Burden of Disease Group. , 2000, American journal of public health.

[30]  M. Koopmanschap,et al.  On the economic foundations of CEA. Ladies and gentlemen, take your positions! , 2000, Journal of health economics.

[31]  C. Murray,et al.  Understanding DALYs (disability-adjusted life years). , 1997, Journal of health economics.

[32]  David O. Meltzer,et al.  Accounting for future costs in medical cost-effectiveness analysis. , 1997 .

[33]  K. Muir,et al.  The relationship between body mass index and health-related quality of life: comparing the EQ-5D, EuroQol VAS and SF-6D , 2007, International Journal of Obesity.

[34]  Jan J. Barendregt,et al.  Disability weights for diseases in the Netherlands , 1997 .